Is weekly paclitaxel superior to paclitaxel given every 3 weeks? Results of a phase II trial
作者： George Koumakis , Matina Demiri , Vassilios Barbounis , Michail Vassilomanolakis , Emmanuel Gontikakis
DOI: 10.1016/S0169-5002(01)00441-X
关键词:
摘要: Abstract Twenty-four patients previously treated with platinum containing regimens stage IIIB–IV non-small-cell lung cancer (NSCLC) participated in the study. Sequential cohorts of were 60 and 90 mg/m 2 Paclitaxel per week. was administered weekly over 1 h infusion for 6 consecutive weeks followed by without treatment (8-week cycle). A total 252 treatments to 24 patients. In 29 (12%) grade granulocytopenia observed while four (17%) developed neuropathy. Seven (29%) achieved a partial response five (21%) had stable disease. week as salvage is well tolerated has shown promising activity NSCLC who progress after treatment.
elsevier.com
sci-hub.se 参考文章(6)
W. Freund, J. Lipke, T.-U. Hausamen, T. M. Löffler, Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial. Seminars in Oncology. ,vol. 23, pp. 32- 34 ,(1996)
J-P Sculier, J-J Lafitte, M Paesmans, J Thiriaux, C G Alexopoulos, J Baumöhl, J Schmerber, G Koumakis, M C Florin, C Zacharias, T Berghmans, P Mommen, V Ninane, J Klastersky, Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. British Journal of Cancer. ,vol. 83, pp. 1128- 1135 ,(2000) , 10.1054/BJOC.2000.1413
J D Hainsworth, D S Thompson, F A Greco, Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. Journal of Clinical Oncology. ,vol. 13, pp. 1609- 1614 ,(1995) , 10.1200/JCO.1995.13.7.1609
J.P Sculier, J.J Lafitte, T Berghmans, J Thiriaux, J Lecomte, A Efremidis, V Ninane, M Paesmans, P Mommen, J Klastersky, A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer Lung Cancer. ,vol. 29, pp. 67- 73 ,(2000) , 10.1016/S0169-5002(00)00099-4
M J Millward, J F Bishop, M Friedlander, J A Levi, D Goldstein, I N Olver, J G Smith, G C Toner, D Rischin, D R Bell, Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology. ,vol. 14, pp. 142- 148 ,(1996) , 10.1200/JCO.1996.14.1.142
H. Safran, Hak Choy, W. Akerley, V. Rege, S. Sambandam, E. Wittels, W. Sikov, Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a phase II trial. Seminars in Oncology. ,vol. 24, ,(1997)